[go: up one dir, main page]

PT3003386T - Conjugados anticorpo-fármaco - Google Patents

Conjugados anticorpo-fármaco

Info

Publication number
PT3003386T
PT3003386T PT147325146T PT14732514T PT3003386T PT 3003386 T PT3003386 T PT 3003386T PT 147325146 T PT147325146 T PT 147325146T PT 14732514 T PT14732514 T PT 14732514T PT 3003386 T PT3003386 T PT 3003386T
Authority
PT
Portugal
Prior art keywords
antibody
drug conjugates
conjugates
drug
Prior art date
Application number
PT147325146T
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of PT3003386T publication Critical patent/PT3003386T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT147325146T 2013-05-31 2014-06-02 Conjugados anticorpo-fármaco PT3003386T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1309807.4A GB201309807D0 (en) 2013-05-31 2013-05-31 Antibody drug conjugates

Publications (1)

Publication Number Publication Date
PT3003386T true PT3003386T (pt) 2020-01-21

Family

ID=48805601

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147325146T PT3003386T (pt) 2013-05-31 2014-06-02 Conjugados anticorpo-fármaco

Country Status (30)

Country Link
US (2) US11224663B2 (pt)
EP (1) EP3003386B1 (pt)
JP (1) JP6412114B2 (pt)
KR (2) KR102340681B1 (pt)
CN (1) CN105451775B (pt)
AR (2) AR096461A1 (pt)
AU (1) AU2014273052B2 (pt)
BR (1) BR112015029816B1 (pt)
CA (1) CA2914041C (pt)
CL (1) CL2015003481A1 (pt)
CY (1) CY1122662T1 (pt)
DK (1) DK3003386T3 (pt)
ES (1) ES2778045T3 (pt)
GB (1) GB201309807D0 (pt)
HR (1) HRP20200032T1 (pt)
IL (1) IL242571B (pt)
LT (1) LT3003386T (pt)
MX (1) MX356431B (pt)
MY (1) MY176579A (pt)
NZ (1) NZ715646A (pt)
PL (1) PL3003386T3 (pt)
PT (1) PT3003386T (pt)
RS (1) RS59855B1 (pt)
RU (1) RU2669812C2 (pt)
SG (1) SG11201509563UA (pt)
SI (1) SI3003386T1 (pt)
SM (1) SMT202000023T1 (pt)
UA (1) UA119327C2 (pt)
WO (1) WO2014191578A1 (pt)
ZA (1) ZA201508487B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170058043A1 (en) * 2014-12-06 2017-03-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
WO2017024032A2 (en) * 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
EP3525824A4 (en) * 2016-10-17 2020-06-10 Shenzhen Enduring Biotech, Ltd. LONG-LASTING MULTI-SPECIFIC MOLECULES AND RELATED PROCEDURES
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
MA51870A (fr) * 2017-11-30 2020-10-07 Seagen Inc Procédé pour la préparation de composés coupleurs de médicaments
KR20200095493A (ko) * 2017-12-01 2020-08-10 애브비 인코포레이티드 항-cd40 항체 약물 공액체
US12070506B2 (en) 2018-01-08 2024-08-27 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
KR20210104672A (ko) * 2018-10-21 2021-08-25 에스엘에스지 리미티드 엘엘씨 삼중음성 유방암의 치료를 위한 병용 면역요법
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN113454097B (zh) 2018-12-21 2024-08-30 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
EP3964236A4 (en) * 2019-05-02 2023-05-31 LegoChem Biosciences, Inc. LIGAND-DRUG CONJUGATE COMPRISING A LINKER HAVING A TRIS STRUCTURE
US20220226496A1 (en) * 2019-05-02 2022-07-21 Legochem Biosciences, Inc. Ligand-drug conjugate including linker having tris structure
CA3139809A1 (en) * 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
KR102440763B1 (ko) * 2019-05-20 2022-09-05 맙플렉스 인터내셔널 컴퍼니 리미티드 항체-약물 접합체의 중간체를 제조하는 원-포트 방법
KR20220039722A (ko) * 2019-07-31 2022-03-29 어드방스드 비오디자인 아미노티올에스터 화합물 및 이의 용도
JP2023522259A (ja) * 2020-04-21 2023-05-29 ファルマ、マール、ソシエダード、アノニマ 薬物抗体コンジュゲート
CN114262377B (zh) * 2021-10-28 2024-03-22 新疆优迈生物技术有限公司 一种阻断cd70与其配体cd27结合的抗人cd70纳米抗体的制备方法及其编码序列
CN115873066A (zh) * 2022-07-27 2023-03-31 吉林省博大伟业制药有限公司 一种抗体偶联药物连接子的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
EP1594542B1 (en) * 2003-02-20 2010-06-30 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
UA97369C2 (ru) * 2006-06-16 2012-02-10 Фарма Мар, С.А. Противоопухолевые соединения дигидропиран-2-она и фармацевтическая композиция на их основе
BRPI0821114B8 (pt) * 2007-12-20 2021-11-09 Pharma Mar Sa Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto
RS55960B1 (sr) 2008-05-23 2017-09-29 Wyeth Llc Triazinska jedinjenja kao inhibitori pi3 kinaze i mtor
AR072804A1 (es) 2008-07-15 2010-09-22 Genentech Inc Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.
WO2010149688A2 (en) * 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds

Also Published As

Publication number Publication date
DK3003386T3 (da) 2020-01-27
KR20160030132A (ko) 2016-03-16
AR123672A2 (es) 2023-01-04
NZ715646A (en) 2019-05-31
SMT202000023T1 (it) 2020-03-13
EP3003386B1 (en) 2019-10-16
RU2015156499A (ru) 2017-06-30
CA2914041C (en) 2021-12-07
KR20210156848A (ko) 2021-12-27
US20160129128A1 (en) 2016-05-12
AR096461A1 (es) 2015-12-30
PL3003386T3 (pl) 2020-04-30
SI3003386T1 (sl) 2020-03-31
EP3003386A1 (en) 2016-04-13
KR102340681B1 (ko) 2021-12-20
US12410148B2 (en) 2025-09-09
BR112015029816B1 (pt) 2022-10-04
WO2014191578A1 (en) 2014-12-04
MY176579A (en) 2020-08-17
KR102448393B1 (ko) 2022-09-28
BR112015029816A2 (pt) 2017-07-25
SG11201509563UA (en) 2015-12-30
UA119327C2 (uk) 2019-06-10
RS59855B1 (sr) 2020-02-28
CN105451775A (zh) 2016-03-30
US20220168436A1 (en) 2022-06-02
AU2014273052B2 (en) 2018-03-08
CY1122662T1 (el) 2021-03-12
IL242571B (en) 2019-10-31
CA2914041A1 (en) 2014-12-04
RU2669812C2 (ru) 2018-10-16
MX356431B (es) 2018-05-29
CN105451775B (zh) 2019-09-06
ZA201508487B (en) 2017-11-29
MX2015016417A (es) 2016-07-05
ES2778045T3 (es) 2020-08-07
GB201309807D0 (en) 2013-07-17
HRP20200032T1 (hr) 2020-03-20
CL2015003481A1 (es) 2016-08-19
LT3003386T (lt) 2020-01-27
JP6412114B2 (ja) 2018-10-24
JP2016526042A (ja) 2016-09-01
RU2015156499A3 (pt) 2018-03-27
US11224663B2 (en) 2022-01-18
AU2014273052A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
FR23C1020I2 (fr) Conjugues pyrrolobenzodiazepine-anticorps
HUS2500038I1 (hu) Anti-trop2 antitest-gyógyszer konjugátum
DK3460054T3 (da) Histidyl-tRNA-syntetase-Fc-konjugater
PT3003386T (pt) Conjugados anticorpo-fármaco
BR112016015105A8 (pt) conjugados var2csa-droga
IL244816B (en) Protein-polymer-drug conjugates
DK3137114T3 (da) Anti-PTK7-antistof-lægemiddelkonjugater
IL245009A0 (en) Attach a drug from a protein and a polymer
DK2906251T3 (da) Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
BR112015008232A2 (pt) conjugados pirrolbenzodiazepina-anticorpo
EP2970511A4 (en) INSULIN CONJUGATES incretin
EP3065716C0 (en) FORMULATIONS
DK3049441T3 (da) Anti-PDL1-antistofformuleringer
EP2987125A4 (en) LINKED ADVERTISING CONTENT
EP2841103A4 (en) DR5 Ligand-drug conjugates
DK2920167T3 (da) Hydrazinyl-indol-forbindelser og konjugater
FR3014828B1 (fr) Trottinette motorisee
DK2917244T3 (da) Aprotinin-afledte polypeptid-antistofkonjugater
DK2952513T3 (da) Azolbenzenderivat
PL2945641T3 (pl) Cykloalkinowe pochodne sacharydów
EP2953978C0 (en) PHOSPHORYLCHOLINE CONJUGATES AND THEIR USES
SG11201604191UA (en) Anti-efna4 antibody-drug conjugates
EP3009444A4 (en) ALPHA-oxoacyl-Amino-caprolactam derivative
GB201310472D0 (en) Antibody-drug conjugates
TH1401007086A (th) อนุพันธ์อัลริลเอทธินิล